Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hrnciar

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Vnitrni Lekarstvi|November 1, 1992
[Hyperinsulinism and the coronary syndrome]J Hrnciar
Vnitrni Lekarstvi|February 21, 2002
[Cor thyreotoxicum. Part I--new findings about its etiopathogenesis and diagnosis. Overview of problems based on 35 years' experience]J Hrnciar
Vnitrni Lekarstvi|February 1, 1995
[Clinical manifestations of the insulin resistance syndrome. The hormonal-metabolic syndrome X, the 5H syndrome and their etiopathogenesis]J Hrnciar
Vnitrni Lekarstvi|April 16, 2002
[Thyrotoxic heart disease. Part II--aspects of treatment of thyrotoxicosis with cardiac involvement]J Hrnciar
Vnitrni Lekarstvi|March 1, 1990
[Is our cardiovascular program effective?]J Hrnciar
Vnitrni Lekarstvi|February 1, 1997
[Leptin and its biological and clinical significance. Is leptin and insulin resistance in the X-5H hormonal metabolic syndrome a parallel or causally-linked phenomenon?]J Hrnciar
Vnitrni Lekarstvi|May 1, 1993
[Methods of measuring hyperinsulinism and insulin resistance]J Hrnciar
Vnitrni Lekarstvi|June 1, 1996
[Diabetic nephropathy and isolated hyporeninemic hypoaldosteronism]J Hrnciar
Vnitrni Lekarstvi|January 1, 1994
[Thyrotoxic crisis]J Hrnciar
Vnitrni Lekarstvi|August 1, 1996
[Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome]J Hrnciar
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Vnitrni Lekarstvi|November 1, 1992
[Hyperinsulinism and the coronary syndrome]J Hrnciar
Vnitrni Lekarstvi|February 21, 2002
[Cor thyreotoxicum. Part I--new findings about its etiopathogenesis and diagnosis. Overview of problems based on 35 years' experience]J Hrnciar
Vnitrni Lekarstvi|February 1, 1995
[Clinical manifestations of the insulin resistance syndrome. The hormonal-metabolic syndrome X, the 5H syndrome and their etiopathogenesis]J Hrnciar
Vnitrni Lekarstvi|April 16, 2002
[Thyrotoxic heart disease. Part II--aspects of treatment of thyrotoxicosis with cardiac involvement]J Hrnciar
Vnitrni Lekarstvi|March 1, 1990
[Is our cardiovascular program effective?]J Hrnciar
Vnitrni Lekarstvi|February 1, 1997
[Leptin and its biological and clinical significance. Is leptin and insulin resistance in the X-5H hormonal metabolic syndrome a parallel or causally-linked phenomenon?]J Hrnciar
Vnitrni Lekarstvi|May 1, 1993
[Methods of measuring hyperinsulinism and insulin resistance]J Hrnciar
Vnitrni Lekarstvi|June 1, 1996
[Diabetic nephropathy and isolated hyporeninemic hypoaldosteronism]J Hrnciar
Vnitrni Lekarstvi|January 1, 1994
[Thyrotoxic crisis]J Hrnciar
Vnitrni Lekarstvi|August 1, 1996
[Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome]J Hrnciar
Pageof 4